| Name | LLY-283 |
| Description | LLY-283 is a potent, selective, and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, exhibiting an IC50 of 22 nM and a Kd of 6 nM for the PRMT5:MEP50 complex, and demonstrates antitumor activity. |
| In vitro | LLY-283 is a potent, oral, and selective arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM in vitro and 25 nM in cells, and a Kd of 6 nM for the PRMT5:MEP50 complex in vitro; LLY-283 inhibits A375 cell proliferation with an IC50 of 46 nM[1]. |
| In vivo | LLY-283 administered orally at a dose of 20 mg/kg daily significantly inhibits tumor growth in A375 cell-bearing mice over a 28-day treatment period[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 3.57 mg/mL (10.43 mM), Sonication and heating to 60℃ are recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (11.68 mM), Sonication is recommended. DMSO : 112.5 mg/mL (328.61 mM), Sonication is recommended.
|
| Keywords | PRMT5 | MEP50 | LLY-283 | LLY283 | LLY 283 | HistoneMethyltransferase | Histone Methyltransferase |
| Inhibitors Related | MAK-683 hydrochloride | SNDX-5613 | Tazemetostat | Piribedil | XY1 | UNC 0631 | (Iso)-Flavokawain A | EPZ015666 | iso-Azalansta | AMI-1 free acid | MS37452 | MRTX-1719 |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Nucleotide Compound Library | High-Efficiency Gene Editing Small Molecule Library |